spacer
home > ict > spring 2008 > solid supply
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

BRIM Biotechnology, Inc. Raises $20 Million in Series E Funding Round

Taipei, Taiwan, 1st December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding round. This demonstrates the heightened interest and growing demand for new treatments for Dry Eye Disease (DED). News of this latest funding round comes as BRIM prepares to initiate the Phase 3 clinical trial for its lead asset BRM421 for DED in the US.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement